Abatacept (Bristol-Myers Squibb, Orencia ®) and Belatacept (Bristol-Myers Squibb, NULOJIX®) are two FDA approved biologics, consisting of the extracellular domain of CTLA-4 fused to the Fc domain from human Ig, used to treat autoimmune diseases and kidney transplant rejection, respectively [46–48]. The gene discussed is CTLA4; the disease is autoimmune disease.